Phynova study reveals ‘real meal’ blood sugar benefits with low dose Reducose

Researchers from Oxford Brookes Centre for Nutrition and Health, UK, and ingredient supplier Phynova Group Limited conducted the double-blind, randomised, placebo-controlled, repeat-measure, crossover design trial to test the efficacy of the white mulberry extract at different doses with meals containing carbohydrates, proteins and fat.

Wouter Claerhout, chief marketing officer at Phynova explained it is imperative that the team ensures Reducose is effective at the right dose, “in order to protect customers and their brands, since consumers who use Continuous Glucose Monitors (CGMs) can see the strong efficacy of Reducose immediately and from the first dose.โ€

Andrew Gallagher, global head of science at the firm,ย added: โ€œThis is the second time that Reducoseย has proven itself in a clinical study with real meal conditions. The Gheldof study by Nestlรฉโ€‹ also showed similar results with 250mg Reducoseย 5% in a meal that included rice, bread, curry sauce and chicken.โ€

The study, funded by Phynova, also demonstrated the efficacy of Reducose does not appear to be overly impacted by the quantity of food eaten as the reduction in post-prandial glucose was of a similar scale as seen with smaller carbohydrate loads.

Spiking interest โ€‹

As predicted by Phynovaโ€‹, interest in blood sugar spikes has taken off in the last couple of years, with the proliferation of CGMs.

The firm has noted the uptick in enquiries in 2024 alone.

โ€œThe pull for Reducose has increased dramatically in the last months,” Wouter told NutraIngredients. “We just witnessed our busiest ever Vitafoods in Geneva with formulators from all markets eager to incorporate Reducose into their formulas.



Source link


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

>